Thinly traded nano cap Catalyst Biosciences (NASDAQ:CBIO) is up 7% premarket on robust volume in response to its announcement of positive results from a Phase 1/2 proof-of-concept study assessing CB 2679d in patients with severe hemophilia B.
An intravenous dose of CB 2679d was ~22x more potent that an intravenous dose of Pfizer's BeneFix [coagulation Factor IX (recombinant)]. The average time in circulation also favored CB 2679d, 34 hours versus 25 hours.
Interim top-line data from the South Korea-based study should be available by year-end with complete results expected in Q1 2018.
CB 2679d is a next-generation coagulation Factor IX variant that has a longer duration of action than other Factor IX products.
Subscribe for full text news in your inbox